


## SARS-CoV-2 Sequencing Update 30 June 2023



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

Department

Science and Innovation

REPUBLIC OF SOUTH AFRICA

The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 30 June 2023 at 08h15



Data license: <a href="https://www.gisaid.org/registration/terms-of-use/">https://www.gisaid.org/registration/terms-of-use/</a>

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101



(ending 10 June 2023)

Currently in epi week 26 (ending 1 July 2023)

40

2022

30

20

10

50 2021

40

50

20

10

Total genomes: 52 371 2020 genomes: 6 795 2021 genomes: 26 443 2022 genomes: 15 438 2023 genomes: 3 695 Genomes added since last report: 274

30

2020

40

50

10

\*This represents the cleaned, de-duplicated dataset of unique National and Pneumonia Surveillance sequences. This dataset will be used for all further figures

20 30 Epidemiological week


20

500 -

10


1500 -

## GISAID genomes vs total cases, 2020 – 2023 (N= 52 371)




NGS-SA Network for Genomic Surveillance in South Africa

#### Number and percentage of clades by epiweek in South Africa, 2022-2023 (19 090\*)




### **Detection Rates: Omicron and recombinants**



Surveillance in South Africa


\*Bars represent percentage prevalence of variant for the month; total number sequences collected for the month are given below the bar

### Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in



Note: XBF is an Omicron-Omicron recombinant and so is counted in the total number of Omicrons.


## South Africa, 2022-2023, n = 19 090\*



\*Excludes sequences missing collection dates. Lineages of particular interest (mainly WHO Omicron subvariants under monitoring) are separate from the main clade groupings. #Recombinants include all recombinant lineages (viruses consisting of segments of two different lineages) detected in South Africa at low levels. Currently it consists of XT, XAS, XAZ, XBA, XBF. NGS-SA Network for Genomic Surveillance in South Africa

## Eastern Cape Province, 2022-2023, n = 971

Genomes added since last report: 20\* EC (N=971)






\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## Free State Province, 2022-2023, n = 648

Genomes added since last report: 38\*



Network for Genomi


Surveillance in South Africa

\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## Gauteng Province, 2022-2023, n = 5588

Genomes added since last report: 99\*

GP (N=5588)




Network for Ge Surveillance in South Africa

\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## KwaZulu-Natal Province, 2022-2023, n = 2129

Genomes added since last report: 22\*

KZN (N=2129)




Surveillance in South Africa

\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## Limpopo Province, 2022-2023, n = 934

Genomes added since last report: 6\*

LP (N=934)




Network for Genomic Surveillance in South Africa

\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## Mpumalanga Province, 2022-2023, n = 1454

Genomes added since last report: 11\*

MP (N=1454)




Surveillance in South Africa

\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## Northern Cape Province, 2022-2023, n = 584

Genomes added since last report: 2\*






\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

## North West Province, 2022-2023, n = 715

Genomes added since last report: 22\*






\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

XAY

XBF

## Western Cape Province, 2022-2023, n = 6046

Genomes added since last report: 54\*





\*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

XAY

XBF

## Summary

#### Sequencing update


 All provinces have sequence data for March and April 2023, except the Northern Cape. May 2023 sequence data are from all provinces. June sequences (n = 3) are from the Eastern Cape and the Western Cape

#### • Variant of Concern Omicron in South Africa

- Omicron continued to dominate in March (99.9%), April (99.6%) and May (100%)
- XBB.1.5 was the dominant lineage in March (78%), April (76%), and May (69%)
- XBB.1.9.1 has been detected in sequences from March (9%), April (12%) and May (19%)
- XBB.1.16 has been detected at a low prevalence in March (1%), April (2%) and May (6%)



## Spike protein mutation\* profile of Variants of Interest and Concern




- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
  - Including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
  - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape

\*Only mutations present in Omicron, Delta, or recombinant sequences are pictured



## BQ.1\* and XBB.1.5\* spike mutations\*



NTD RBD RBM S1

#### **University of Stellenbosch** & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga **Bronwyn Kleinhans** Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen **Diagnostic laboratory staff** 

This project has

Horizon Europe

Research and

under grant No.

101046041

#### **UKZN-Inkosi Albert Luthuli Central Hospital**

UNIVERSITY OF INYUVES YAKWAZULU-NATALI

Dr Khanvi Msomi Dr Neli Ngcaba Dr Kerusha Govender Dr Tshepiso Mosito Dr Pravi Moodley Mr Malcolm Ellapen Dr Aabida Khan Mr Kubendran Reddy Dr Lili Gounder The COVID-19 Bench team Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty

#### University of KwaZulu-Natal & Africa **Health Research Institute**



Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San** 

KRISP at UKZN:



#### National Institute for Communicable Diseases



**Centre for Respiratory** Diseases & Meningitis Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter

Mignon du Plessis Stefano Tempia Mvuyo Makhasi Cheryl Cohen

Sequencing Core Facility Zamantungwa Khumalo Annie Chan Morne du Plessis Stanford Kwenda Mushal Allam Florah Mnvameni





#### University of Cape Town, NHLS & Western Cape Government



NHLS Greenpoint Mary-Anne Davies Annabel Enoch Hannah Hussev Andrew Boulle Masudah Paleker

Theuns Jacobs Erna Morden



Nei-yuan Hsiao

Diana Hardie

Kruger Marais

Stephen Korsman

Ziyaad Valley-Omar

#### UCT. IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Nokuzola Mbhele Fezokuhle Khumalo Thabang Serakge Bruna Galvão Linda Boloko Arghavan Alisoltani (U. California)



centre infectious ( AA EDCTP W Robert Wilkinson Darren Martin

Nicola Mulder Samrc Wendy Burgers Ntobeko Ntusi CAPE TOWN HVTN Rageema Joseph Sean Wasserman

> cience & innovation epartment: dense and knowation EPUBLIC OF SOUTH AFRICA

Zoonotic arbo and respiratory virus program **Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria** 

> ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist) Carien van Niekerk

NHLS Tshwane Prof Simnikiwe Mayaphi (HOD)

#### Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

#### Cathrine Scheepers Thandeka Movo

Sibongile Walaza



Phillip Senzo Mtshali











University of the

**Free State** 

**Dominique Goedhals** 

Emmanuel Ogunbayo

Makgotso Maotoana

NHLS Division of Virology

**Diagnostic laboratory staff** 

Lutfiyya Mohamed

Sabeehah Vawda

Thokozani Mkhize

Felicity Burt

Armand Bester

Martin Myaga

Peter Mwangi

Milton Mogotsi

UNIVERSITY OF THE FREE STATE UNIVERSITEIT VAN DIE VRYSTAAT YUNIVESITHI Y FREISTA'

UFS

Centre for HIV and STIs **Jinal Bhiman** 

**Constantinos Kurt Wibmer Tandile Hermanus** Frances Ayres Zanele Molaudzi Bronwen Lambson **Tandile Hermanus** 

Prudence Kgagudi

**Brent Oosthuysen** 

Penny Moore







**NICD Groups** 

NICD COVID-19 response team NICD SARS-CoV-2 Sequencing















Lynn Morris

## Arshad Ismail





## 

Key to Diagnostic Excellence

ΑΜΡΑΤΗ

LABORATORIES

1

PathCare

Vermaak

africa

aboratorie

FIOCRUZ



**Hyrax Biosciences** Simon Travers

**Cape Town HVTN Laboratory** Erica Anderson-Nissen Anneta Naidoo

Ndlovu Research Hugo Tempelman CJ Umunnakwe

#### Additional support and collaborators

Lancet Allison J. Glass Raguel Viana

Ampath Terry Marshall Cindy van Deventer Eddie Silberbauer

Pathcare Vermaak Andries Dreyer Howard Newman Riaan Writes Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

**Cytespace Africa Laboratories** Christa Viljoen

ARC-OVI Lia Rotherham **CAPRISA** Salim Abdool Karim Nigel Garret

UKZN - Big Data Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara Africa CDC and Africa PGI John Nkengasong Sofonias Tessema

Netcare Richard Friedland Craig Murphy Caroline Maslo Liza Sitharam

#### DSI

Glaudina Loots

**SA MRC** Glenda Gray

Pathcare N1 City Jean Maritz Nadine Cronje Petra Raimond Kim Hoek























**NATIONAL HEALTH** LABORATORY SERVICE

**X**X


ЕDСТР

3030) is part of the

European Union"

EDCTP2 programme supported by the

## South African genomes submitted per submitting lab, 2020 - 2023 (N=52 371)



Submitting labs in South Africa

**NGS-SA Labs** 

CERI: Centre for Epidemic Response and Innovation KRISP: KZN Research Innovation and Sequencing Platform NDLOVU: Ndlovu Research Laboratories NICD: National Institute for Communicable Diseases NHLS: National Health Laboratory Service SU: Stellenbosch University UCT: University of Cape Town UFS: University of the Free State UP: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



## Currently circulating Variants of Interest (VOI) as of 5 June 2023

Pango lineage	Nextstrain clade	Genetic features	Earliest documented samples	Date of designation
XBB.1.5	23A	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1, with a breakpoint in S1.	05-01-2022	11-01-2023 <u>XBB.1.5 Rapid Risk</u> <u>Assessment, 11 January 2023</u> <u>XBB.1.5 Updated Rapid Risk</u> <u>Assessment, 25 January 2023</u>
		XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.9.1)		XBB.1.5 Updated Risk Assessment, 24 February 2023
XBB.1.16	23B	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB.1 + S:E180V, S:K478R and S:F486P	09-01-2023	17-04-2023 <u>XBB.1.16 Initial Risk</u> <u>Assessment 17 April 2023</u> <u>XBB.1.16 Updated Risk</u> Assessment, 05 June 2023

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 15 June 2023

## **Currently circulating variants under monitoring (VUMs)**

Pango lineage <sup>#</sup> (+ mutation)	Nextstrain clade	Spike genetic features	Earliest documented samples	Date of designation and risk assessments
BA.2.75	22D	BA.2 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion	31-12-2021	06-07-2022
CH.1.1	22D	BA.2.75 + S:L452R, S:F486S	27-07-2022	08-02-2023
BQ.1	22E	BA.5 + S:R346T, S:K444T, S:N460K	07-02-2022	21-09-2022
XBB*	22F	BA.2+ S:V83A, S:Y144-, S:H146Q, S:Q183E, S:V213E, S:G252V, S:G339H, S:R346T, S:L368I, S:V445P, S:G446S, S:N460K, S:F486S, S:F490S	13-08-2022	12-10-2022
XBB.1.9.1	Not assigned	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.5)	05-12-2022	30-03-2022
XBB.1.9.2	Not assigned	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB.1 + S:F486P, S:Q613H	05-12-2022	26-04-2023
XBB.2.3	Not assigned	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB + S:D253G, S:F486P, S:P521S	09-12-2022	17-05-2023

\* Excludes XBB sublineages listed here as VOIs and VUMs <u>https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</u> accessed 15 June 2023

## Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
  - all ages
  - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
  - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
  - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

# Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)